XSWXIDIA
Market cap146mUSD
Dec 23, Last price
0.73CHF
1D
15.42%
1Q
-46.72%
IPO
-94.95%
Name
Idorsia Ltd
Chart & Performance
P/E
—
P/S
0.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.11%
Rev. gr., 5y
20.25%
Revenues
152m
+56.93%
Net income
-298m
L-64.01%
CFO
-629m
L-26.75%
Dividend
Jun 16, 201712 CHF/sh
Earnings
Feb 05, 2025
Profile
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 152,386 56.93% | 97,102 174.70% | 35,349 -50.74% | |||||
Cost of revenue | 680,720 | 1,072,029 | 665,910 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (528,334) | (974,927) | (630,561) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 3,668 | 7,807 | (210) | |||||
Tax Rate | ||||||||
NOPAT | (532,002) | (982,734) | (630,351) | |||||
Net income | (297,921) -64.01% | (827,896) 30.46% | (634,595) 42.57% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (197) | 360 | 9,582 | |||||
BB yield | 0.05% | -0.02% | -0.31% | |||||
| Debt | ||||||||
Debt current | 206,122 | 8,921 | 10,312 | |||||
Long-term debt | 1,070,280 | 1,315,993 | 1,224,047 | |||||
Deferred revenue | 3,518 | |||||||
Other long-term liabilities | 167,944 | 169,873 | 55,916 | |||||
Net debt | 1,118,586 | 848,442 | 972,957 | |||||
| Cash flow | ||||||||
Cash from operating activities | (629,296) | (859,108) | (589,895) | |||||
CAPEX | (9,131) | (27,058) | (30,931) | |||||
Cash from investing activities | 632,614 | 743,901 | (53,257) | |||||
Cash from financing activities | (197) | 162,310 | 604,146 | |||||
FCF | (519,532) | (1,004,766) | (657,563) | |||||
| Balance | ||||||||
Cash | 157,816 | 476,324 | 1,038,125 | |||||
Long term investments | 148 | (776,723) | ||||||
Excess cash | 150,197 | 471,617 | 259,635 | |||||
Stockholders' equity | (3,133,595) | (2,787,817) | (1,973,231) | |||||
Invested Capital | 3,536,445 | 3,524,086 | 3,300,353 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 178,247 | 177,434 | 168,498 | |||||
Price | 2.11 -84.28% | 13.42 -28.00% | 18.64 -26.96% | |||||
Market cap | 376,101 -84.21% | 2,381,164 -24.19% | 3,140,803 -13.82% | |||||
EV | 1,494,687 | 3,229,606 | 4,136,562 | |||||
EBITDA | (509,300) | (955,098) | (612,528) | |||||
EV/EBITDA | ||||||||
Interest | 20,668 | 17,172 | 27,937 | |||||
Interest/NOPBT | ||||||||